Verve Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the following May investor conferences:

• BofA Securities 2022 Healthcare Conference (formal presentation) on Wednesday, May 11, 2022, at 2:40 p.m. PT in Las Vegas; and,
• 2022 RBC Capital Markets Global Healthcare Conference (fireside chat) on Wednesday, May 18, 2022, at 1:35 p.m. ET in NYC.

Live webcasts will be available in the investor section of the company's website at www.vervetx.com and will be archived for 60 days following the presentations.

About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
[email protected]

Media Contact
Gina Nugent
Ten Bridge Communications
[email protected]

You May Also Be Interested In

• Correction: QTREX Establishes Cryogenic Interconnect Capacity, More Than Four Times the Highest Publicly Disclosed Industry Benchmark
• Six-months results of AB Rokiskio suris Group for 2026
• The AI Boom's Real Bottleneck Isn't Chips Anymore. It's Power-Ready Land, and One Lease Just Proved What It's Worth